Share

July 18, 2017; 89 (3) Editorial

Is all ALS genetic?

Peter M. Andersen
First published June 22, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004127
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
189

Share

Article Information

vol. 89 no. 3 220-221
DOI: 
https://doi.org/10.1212/WNL.0000000000004127
PubMed: 
28642337
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published June 22, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Peter M. Andersen, MD, PhD
  1. Peter M. Andersen, MD, PhD
    2. Scientific Advisory Boards:

    1. Commercial: Advisory board for Biogen Idec for clinical trial of new drugs relevant to the genetics of ALS. Received compensation. Advisory board for Orphazyme for clinical trial of a new drug relevant to the genetics of ALS. Received compensation.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial: funding for travel to advisory board meetings for Biogen Idec and Orphazyme Non-profit: funding for travel to meetings for non-for profit meetings for patient organizations in the Norway and Sweden.

    Editorial Boards:

    1. Member of the Editorial Advisory board for the journal “Amyotrophic lateral sclerosis and Frontotemporal Degeneration”, since 2007. (No economic compensation given)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Received compensation for speeches to non-for profit patient organizations in Sweden, Norway and Denmark.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. RESEARCH GRANTS: The Swedish Medical Research Council, since 2007 (multiple)(#521-2012- 3167) County of Vasterbotten, Sweden (#7002678, #7002829) Ume? University Research Foundation (#2.1.12-1605-14)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Swedish Brain Research foundation, annually since 1998. (#2016- 0303). Swedish Brain Power Society, annually 2004-2015. The Swedish patients organization (many years, many smaller grants). The Knut and Alice Wallenberg Foundation (KAW): Project grant 2013- 2017 (KAW #2012.0091) The Knut and Alice Wallenberg Foundation Clinical Scholarship 2016- 2020 (KAW #2014.0305)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Pharmacology and Clinical Neuroscience, Umeå University, Sweden.
  1. Correspondence to Dr. Andersen: Peter.Andersen{at}umu.se
View Full Text

Article usage

Article usage: June 2017 to May 2023

AbstractFullPdfSource
Jun 2017546036Highwire
Jul 20177304455Highwire
Aug 2017951117Highwire
Sep 20172927Highwire
Oct 20174103Highwire
Nov 20172521Highwire
Dec 20172024Highwire
Jan 20184521Highwire
Feb 20183723Highwire
Mar 20184644Highwire
Apr 20184425Highwire
May 20183725Highwire
Jun 20182501Highwire
Jul 20182111Highwire
Aug 20181710Highwire
Sep 20181702Highwire
Oct 20181401Highwire
Nov 20182516Highwire
Dec 20181601Highwire
Jan 20191500Highwire
Feb 20191201Highwire
Mar 20191522Highwire
Apr 2019900Highwire
May 20191310Highwire
Jun 20192412Highwire
Jul 20192441Highwire
Aug 20191431Highwire
Sep 20191012Highwire
Oct 20191502Highwire
Nov 20192714Highwire
Dec 2019310Highwire
Jan 20202321Highwire
Feb 20202111Highwire
Mar 20201210Highwire
Apr 20202000Highwire
May 20202700Highwire
Jun 2020710Highwire
Jul 20201903Highwire
Aug 20201201Highwire
Sep 20202200Highwire
Oct 2020413Highwire
Nov 2020810Highwire
Dec 20201900Highwire
Jan 20212312Highwire
Feb 20213500Highwire
Mar 2021500Highwire
Apr 2021801Highwire
May 2021731Highwire
Jun 20211300Highwire
Jul 2021700Highwire
Aug 20211500Highwire
Sep 20211510Highwire
Oct 20211500Highwire
Nov 20211300Highwire
Dec 2021600Highwire
Jan 2022900Highwire
Feb 20222000Highwire
Mar 20222000Highwire
Apr 20221210Highwire
May 20222003Highwire
Jun 20221000Highwire
Jul 20221701Highwire
Aug 20221211Highwire
Sep 2022501Highwire
Oct 20221700Highwire
Nov 20221200Highwire
Dec 20221100Highwire
Jan 20231000Highwire
Feb 2023510Highwire
Mar 20231600Highwire
Apr 2023611Highwire
May 20231911Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles